Abstract: Methods for the retreatment, using a therapeutically effective amount of interferon consensus, of patients with HCV who exhibit serum ALT values above the upper limit of normal after previous treatment with interferon.

Abstract: The present invention relates to a process for purifying polyethylene glycols (PEGs) which utilizes hydrophobic interaction chromatography (HIC) to separate the PEGs based on their size and on their end-group functionality. The purified PEGs can be used to modify biologically active molecules and improve overall production of such molecules.

Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.

Abstract: The invention relates to stable compositions of proteins and related methods wherein a protein capable of transitioning into the molten globular state is contacted with a negatively charged lipid vesicle, thereby stabilizing the protein against thermally-induced aggregation, denaturation, and loss of activity. The protein:phospholipid complex directly stabilizes the secondary and tertiary structure of the protein, and the compositions are useful in high temperature formulations and in novel delivery vehicles.

Abstract: Stem cell factor in combination with soluble interleukin-6 receptor, interleukin-6, for gp130 signaling, supports the proliferation, differentiation and terminal maturation of blood cells from normal human hematopoietic multipotential cells.

Abstract: Processes for isolating and purifying granulocyte colony stimulating factor (G-CSF) from a G-CSF producing microorganism are disclosed. The simplified processes include steps of lysing the microorganism and separating insoluble material containing G-CSF from soluble proteinaceous material; extracting the material with deoxycholate (optionally); solubilizing and oxidizing the G-CSF in the presence of a denaturant solubilizing agent and an oxidizing agent; removing the denaturant solubilizing agent from the G-CSF; subjecting the G-CSF to ion exchange chromatography; and recovering the purified G-CSF; yet excludes other cumbersome purification steps.

Abstract: Stem cell factor in combination with gp130 signaling supports proliferation, differentiation and terminal maturation of erythroid cells from normal human hematopoietic stem cells.

Abstract: The present invention relates to a process for purifying polyethylene glycols (PEGs) which utilizes hydrophobic interaction chromatography (HIC) to separate the PEGs based on their size and on their end-group functionality. The purified PEGs can be used to modify biologically active molecules and improve overall production of such molecules.

Abstract: The present invention relates to an improved method for the cytoplasmic delivery of oligonucleotides using cationic copolymers based on vinyl alcohol with low levels of vinyl amine (PVAVAMs). Improved compositions for use in such method are also provided.

Abstract: Stem cell factor in combination with interleukin-6 and soluble interleukin-6 receptor supports proliferation, differentiation and terminal maturation of erythroid cells from normal human hematopoietic stem cells.

Abstract: Compositions and methods for treating or preventing infections in canine or feline animals which comprises administering an effective amount of granulocyte colony stimulating factor (G-CSF), are disclosed. The G-CSF may be naturally derived, or alternatively, the G-CSF and genetically engineered variants of G-CSF may be the expression products of genetically engineered prokaryotic or eukaryotic host cells.

Abstract: Disclosed and claimed are toluene monooxygenase (TMO) gene sequences from Pseudomonas mendocina KR-1, TMO proteins encoded by these sequences, recombinant plasmids containing such sequences, and microorganism host cells containing such plasmids. A five-gene and six-gene TMO gene cluster encode proteins that are useful in a variety of bioconversions. In particular, the TMO gene cluster is useful fort he preparation of p-hydroxyphenylacetic acid and indigo. In addition, the TMO gene cluster is useful for the degradative bioconversion of toxic compounds, such as trichloroethylene.

Abstract: The present invention involves a variety of assay methods and devices for screening or diagnosing the occurrence of extrahepatic biliary atresia. In particular the methods and devices involve an antibody specifically for the detection of dipeptidyl peptidase IV in a test sample as indicative of extrahepatic biliary atresia.

Abstract: DNA molecules encoding a modified tryptophan synthase beta subunit are disclosed. When expressed in a recombinant host microorganism, these polypeptide analogs enable significant levels of intracellular indole production and accumulation. In the presence of an aromatic dioxygenase enzyme, the indole so produced can be converted to indoxyl, which upon exposure to air oxidizes to indigo.

Abstract: Compositions and methods for treating or preventing infections in canine or feline animals which comprises administering an effective amount of granulocyte colony stimulating factor (G-CSF), are disclosed. The G-CSF may be naturally derived, or alternatively, the G-CSF and genetically engineered variants of G-CSF may be the expression products of genetically engineered prokaryotic or eukaryotic host cells.

Abstract: The invention relates to the effects of certain cell culture and/or production parameters on the carbohydrate composition of a cell culture-derived recombinant glycoprotein. The methods of the invention demonstrate a practical method for controlling levels of a sialic acid derivative, NGNA, in secreted recombinant glycoproteins which will be useful in a variety of bioprocessing systems.

Abstract: A class of subtilisin analogs suitable for admixture to cleaning compositions and having improved stability over naturally occurring Bacillus subtilisins are prepared by expressing a modified gene encoding the subtilisin analog in Bacillus subtilis.

Abstract: Methods for the treatment of cell proliferation disorders, viral infections, and other conditions without causing significant side effects normally associated with interferon therapy, involving administering to a patient in need thereof a therapeutically effective amount of consensus human leukocyte interferon are disclosed. Also disclosed are pharmaceutical compositions of consensus human leukocyte interferon.